Riding the tide of biopharming in Africa: Considerations for risk assessment

South African Journal of Science

Volumn 102, Issue 7-8, 2006, Pages 284-288

  Chakauya, Ereck ^a,b,c   Chikwamba, Rachel ^c   Rybicki, Edward P ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c DSI CSIR Nanotechnology Innovation Centre   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE FUEL; BIOTECHNOLOGY; DEVELOPING WORLD; DRUG; ENVIRONMENTAL IMPACT ASSESSMENT; PHARMACEUTICAL INDUSTRY; PHYTOREMEDIATION; PLANT PRODUCT; REGULATORY APPROACH; RISK ASSESSMENT; SOCIOECONOMIC CONDITIONS;

AFRICA; SOUTH AFRICA; SOUTHERN AFRICA; SUB-SAHARAN AFRICA;

ANIMALIA;

EID: 33846416230     PISSN: 00382353     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. James C. (2005). Preview: Global status of commercialized biotech/GM crops. ISAAA Briefs 34-2005. Online: http://www.isaaa.org
2. Ma J.K., Chikwamba R., Sparrow P., Fischer R., Mahoney R. and Twyman R.M. (2005). Plant-derived pharmaceuticals - the road forward. Trends Plant Sci. 10, 580-585.
3. Eapen S., Suseelan K.N., Tivarekar S., Kotwal S.A. and Mitra R. (2003). Potential for rhizofiltration of uranium using hairy root cultures of Brassica juncea and Chenopodium amaranticolor. Environ. Res. 91, 127-133.
4. Alkorta I., Hernandez-Allica J. and Garbisu C. (2004). Plants against the global epidemic of arsenic poisoning. Environ. Int. 30(7), 949-951.
5. 2. J. Biotechnol. 123, 43-49.
6. Sethuraman N. and Stadheim T.A. (in press). Challenges in therapeutic glycoprotein production. Curr. Opin. Biotechnol.
7. Fischer R., Stoger E., Schillberg S., Christou P. and Twyman K.M. (2004). Plant-based production of pharmaceuticals. Curr. Opin. Plant Biol. 7, 152-158.
8. Webster D.E., Thomas M.C., Pickering R., Whyte A., Dry I.B., Gorry PR. and Wesselingh S.L. (2005). Is there a role of plant-made vaccines in the prevention of HIV/AIDS? Immunol. Cell Biol. 83, 239-247.
9. Mitchell V.S., Philipose N.M. and Sanford J.P (Eds) (1993). The Children's Vaccine Initiative: Achieving the vision. National Academy Press, Washington, D.C.
10. Walmsley A.M., Kirk D.D. and Mason H.S. (2003). Passive immunisation of mice pups through oral immunization of dams with a plant-derived vaccine. Immunol. Lett. 86, 71-76.
11. Bloomberg News (2005). Syngenta, Bayer bet gene-based drugs can thwart consumer doubts, 27 May 2005. Online: http://quote.bloomberg.com/apps/news?pid= nifea&&sid=adT0ydpQc5Gg
12. Hood E.E. and Woodward J.A. (Eds) (2002). Plants as Factories for Protein Production. Kluwer Academic, Dordrecht.
13. Huang Z. and Mason H.S. (2004). Conformational analysis of hepatitis B surface antigen fusions in an Agrobacterium-mediated transient expression system. Plant Biotech. J. 2, 241-249.
14. Huang Z., Santi L., LePore K., Kilbourne J., Arntzen C.J. and Mason H.S. (2006). Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 24(14), 2506-2513.
15. Voinnet O., Rivas S., Mestre P. and Baulcombe D. (2003). An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. Plant J. 33, 949956.
16. Sunil Kumar G.B., Ganapathi T.R., Revathi C.J., Prasad K.S. and Bapat V.A. (2003). Expression of hepatitis B surface antigen in tobacco cell suspension cultures. Protein Expr. Purif. 32(1), 10-17.
17. Tsuda S.K., Yoshioka K., Tanaka T. et al. (1998). Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis. Vox Sang. 74, 148-155.
18. Koya V, Moayeri M., Leppla S.H. and Daniell H. (2005). Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun. 73, 8266-8274.
19. Zhang X., Buehner N.A., Hutson A.M., Estes M.K. and Mason H.S. (2006). Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotech. J. 4, 419-432.
20. Lee M.W. and Yang Y. (2006). Transient expression assay by agroinfiltration of leaves. Methods Mol. Biol. 323, 225-229.
21. Haviv S., Galiakparov N., Goszczynski D.E., Batuman O., Czosnek H. and Mawassi M. (2006). Engineering the genome of grapevine virus A into a vector for expression of proteins in herbaceous plants. J. Virol Methods 132, 227-231.
22. Fischer R. and Emans N. (2000). Molecular farming of pharmaceutical proteins. Transgenic Res. 9, 279-299.
23. Hood E.E. (2004). Bioindustrials and biopharmaceutical products from plants. In New Directions for a Diverse Planet. Proc. 4th International Crop Science Conference, 26 September - 1 October, Brisbane. Online: www.cropscience.org.au.
24. Lawrence S.D., Kline K. and Moore G.A. (1997). Chromoplast development in ripening tomato fruit: identification of cDNAs for chromoplast-targeted proteins and characterisation of cDNA encoding a plastid-localised low molecular-weight heat shock proteins. Plant Mol. Biol. 33, 483-492.
25. Kermode A. (1996). Mechanisms of intracellular protein transport and targeting in plant cells. Crit. Rev. Plant Sci. 15, 285-423.
26. Maliga P. (2002). Engineering the plastid genome of higher plants. Curr. Opin. Plant Biol. 5, 164-172.
27. Conrad U. and Fiedler U. (1998). Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol. Biol. 38, 101-109.
28. Ervin D., Welsh R., Batie S. and Carpentier C. (2003). Towards an ecological systems approach in public research for environmental regulation of transgenic crops. Agric., Ecosyst., Environ. 99, 1-14.
29. Hilbeck A. and Andow D. (2004). Environmental Risk Assessment of Genetically Modified Organisms, vol. 1: A Case Study of Bt Maize in Kenya. CABI Publishing, Cambridge.
30. Kaplinski N., Braun D., Lisch E., Hay A., Hake S. and Freeling M. (2002). Maize transgene results in Mexico are artifacts. Nature 416, 601.
31. McGeoch M.A. and Pringle K.L. (2005). Science and advocacy: the GM debate in South Africa . S. Afr. J. Sci. 101, 7-9.
32. Raven PH. (2005). Transgene in Mexico maize: desirability or inevitability. Proc. Natl Acad. Sci. USA 102, 13003-13004.
33. Ezcurra E., Ortiz S. and Soberón Mainero J. (2001). In LMOs and the Environment, ed. C.R. Roseland, pp. 286-295. Organization for Economic Cooperation and Development, Paris.
34. Castle D. and Dalgleish J. (2005). Cultivating fertile ground for the introduction of plant-derived vaccines in developing countries. Vaccine 23, 1881-1885.
35. IRIN (2006). South Africa-Zimbabwe: government to regularise farm workers. UN Integrated Regional Information Networks. Online: http://www.irinnews.org (accessed 6 March 2006).
36. Pew Initiative on Biotechnology (2003). Have transgenes - will travel. Issues raised by geneflow from genetically engineered crops. Pew Initiative on Food and Biotechnology, Washington, D.C. Online: http://www.pewagbiotech. org.
37. Emberlin J. (2000). An assessment of outcrossing in maize, relevant to the proposed decision to add GM maize variety Chardon LL. Evidence submitted at the National Seed List Hearings, October to November 2000, Manchester and London.
38. Thompson C., Squire G.R., Mackay G., Bradshaw J., Crawford J. and Ramsay G. (1999). Regional patterns of geneflow and its consequences for GM oilseed rape. In Geneflow in Agriculture: Relevance for transgenic crops. Proc. BCPC Symposium 72, 95-100.
39. Squire G.R., Rodger S. and Wright G.M. (2000). Community-scale seedbank response to less intense rotation and reduced herbicide input at three sites. Ann. Appl. Biol. 136, 47-57.
40. Bates S.L., Zhao J.Z., Roush R.T. and Shelton A.M. (2005). Insect resistance management in GM crops: past, present and future. Nature Biotechnology 23, 57-62.
41. Zhao J.Z., Cao J., Li Y, Collins H.L., Roush R.T., Earle E.D. and Shelton A.M. (2003). Transgenic plants expressing two Bacillus thuringiensis toxins delay insect resistance evolution. Nature Biotechnology 21, 1493-1497.
42. Food and Drug Administration (2002). Guidance for industry: drugs, biologies, and medical devices derived from bioengineered plants for use in human and animals. Online: http://www.fda.gov/cyber/gdlns/bioplant.pdf. Washington, D.C.
43. European Agency for the Evaluation of Medicinal Products. Online: http://www.emea.eu.int/pdfs/human/bwp/076402en.pdf
44. Sweeney P.A. (2002). A warehouse of ideas: Developing and using intellectual property. In Plants as Factories for Protein Production, eds E.E. Hood and J.A. Howard, pp. 159-174. Kluwer Academic, Dordrecht.
45. Ashton G. (2006). Intellectual property rules suit the wealthy. Critical health perspectives 2. People Health Movement South Africa, 91, 127-133. Online: http://www.phmovement.org
46. Menkhaus T., Bai Y, Zhang C., Nikolov Z. and Glatz C. (2004). Considerations for the recovery of recombinant proteins from plants. Biotechnol. Prog. 20, 1001-1014.
47. IOL (2005). Typhoid epidemic: hundreds of cases reported. Independent online, 21 September: Online: http://www.iol.co.za
48. Leshner A. (2002). Science and sustainability. Science 297, 897.
49. Daniell H. (2002). Molecular strategies for gene containment in transgenic crops. Nature Biotechnology 20, 581-586.
50. Pew Initiative on Biotechnology (2003). Pharming in the Field: A look at the risks and benefits of bioengineering plants to produce pharmaceuticals. Washington, D.C.